Osimertinib: First Global Approval

2016/01/04 by Sarah L. Greig · 26 citations
Medicine · #Adjuvant #Cancer #Clinical trial #Colorectal Cancer Treatments and Studies #Epidermal growth factor receptor #Erlotinib #Gefitinib #Internal medicine #Lung Cancer Research Studies #Lung Cancer Treatments and Mutations #Lung cancer #Medicine #Oncology #Osimertinib #Pharmacology #T790M

paper · doi:10.1007/s40265-015-0533-4

openalex publication_date 2016/01/04 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28

Cited by

• A Highly Reactive Cysteine-Targeted Acrylophenone Chemical Probe That Enables Peptide/Protein Bioconjugation and Chemoproteomics Analysis
• Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach. [europepmc]
• Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. [europepmc]
• Circulating tumor cells and CDX models as a tool for preclinical drug development. [europepmc]
• Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients. [europepmc]
• Addressing the challenges of applying precision oncology. [europepmc]
• A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. [europepmc]
• Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. [europepmc]
• Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S. [europepmc]
• Role of Indole Scaffolds as Pharmacophores in the Development of Anti-Lung Cancer Agents. [europepmc]
• Top Notch Targeting Strategies in Cancer: A Detailed Overview of Recent Insights and Current Perspectives. [europepmc]
• The Role of Micro-RNAs and Circulating Tumor Markers as Predictors of Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer. [europepmc]
• Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States. [europepmc]
• Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. [europepmc]
• Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism. [europepmc]
• GA4GH: International policies and standards for data sharing across genomic research and healthcare. [europepmc]
• Liquid Biopsy: A Distinctive Approach to the Diagnosis and Prognosis of Cancer. [europepmc]
• Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021. [europepmc]
• FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. [europepmc]
• Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. [europepmc]
• Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities. [europepmc]
• Retrosynthesis prediction using an end-to-end graph generative architecture for molecular graph editing. [europepmc]
• Recent Advances in Covalent Drug Discovery. [europepmc]
• Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective. [europepmc]
• Recent advances in non-small cell lung cancer targeted therapy; an update review. [europepmc]
• Indole-containing pharmaceuticals: targets, pharmacological activities, and SAR studies. [europepmc]